| Sep-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sep-2024 | |
|---|---|---|---|---|---|
Promoter  | -  | -  | -  | -  | -  | 
Foreign  | 0%  | 0%  | 0%  | 0%  | 0%  | 
Indian  | 72.47%  | 72.47%  | 72.47%  | 72.48%  | 72.86%  | 
Total Promoter  | -  | -  | -  | -  | -  | 
Institutions  | 2.86%  | 2.3%  | 2.65%  | 1.54%  | 1.53%  | 
Non-Institutions  | 24.65%  | 25.21%  | 24.86%  | 25.96%  | 25.59%  | 
Total Non-Promoter  | 27.52%  | 27.52%  | 27.52%  | 27.51%  | 27.13%  | 
Custodian  | 0%  | 0%  | 0%  | 0%  | 0%  | 
Total  | 100%  | 100%  | 100%  | 100%  | 100%  | 
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.